Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 3Carcinoma, Squamous Cell 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Neoplasms, Squamous Cell 1Melanoma 1Lymphoma 1Liver Neoplasms 1Hodgkin Disease 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma 1

Interventions

Oxaliplatin 81S 1 (combination) 55Capecitabine 44apatinib 32Paclitaxel 32Docetaxel 32Irinotecan 27Fluorouracil 22Drug Therapy 21sintilimab 20Cisplatin 20Leucovorin 16Hyperthermic Intraperitoneal Chemotherapy 13XELOX 12Surgical Procedures, Operative 12camrelizumab 10Trastuzumab 10titanium silicide 9Tegafur 9Nivolumab 9Neoadjuvant Therapy 9pembrolizumab 8Laparoscopy 8Gastrectomy 8Folfox protocol 7Chemotherapy, Adjuvant 7toripalimab 6tislelizumab 6Ramucirumab 6Gastroscopy 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Stomach Neoplasms × advexin × Clear all
NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

MultiVir, Inc.

Phase 2 Unknown
40 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡